The Latest Cardiac and Vascular News
Company increases sales efforts and strategy, adds new National Account Executives to accelerate commercial growth Strengthens marketing team with new marketing and communications programs highlighting competitive market advantage BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity […]
As we approach National Cholesterol Education Month, My Cholesterol will provide millions of users with clarity on their cholesterol and triglycerides trends through personalized, gender-specific insights and coaching MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced a new cholesterol management feature, designed to […]
– Appointed Kate Hermans as Interim Chief Executive Officer – SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today provided a corporate update and reported financial results for the first half […]
BOSTON, Aug. 29, 2022 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced completion of the first eShunt® procedure in the United States. The study, ‘US Pilot Study of the CereVasc eShunt System in Normal Pressure Hydrocephalus (NPH)’, is being conducted under an investigational device […]
SAN CARLOS, Calif., Aug. 29, 2022 /PRNewswire/ — Galaxy Medical today announced that it received the CE Mark for its CENTAURI Pulsed Electric Field (PEF) System and launched its commercial program. The approval allows the company to market the system for the treatment of paroxysmal atrial fibrillation (AF) in the European Union […]
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don’t receive either a heart pump or heart transplant is […]
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and Simultaneously Published in Circulation THOUSAND OAKS, Calif., Aug. 29, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented new […]
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA, Spain, Aug. 28, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead […]
– ACCESS 2 is a randomized clinical trial evaluating Sirogen for improving hemodialysis AV Fistula outcomes – CRESSKILL, N.J., Aug. 29, 2022 /PRNewswire/ — Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced that the first patient in the ACCESS 2 […]
— Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis — –– Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular […]
